PHARMACOKINETICS OF 5-FLUOROURACIL AFTER INTRAVENOUS-INFUSION OF 5-FLUOROURACIL-ACETIC ACID-HUMAN SERUM-ALBUMIN CONJUGATES TO RABBITS

被引:0
|
作者
CHUNG, SM
YOON, EJ
KIM, SH
LEE, MG
LEE, H
PARK, MK
KIM, CK
机构
[1] SEOUL NATL UNIV,COLL PHARM,SAN 56-1,SEOUL 151742,SOUTH KOREA
[2] DUKSUNG WOMENS UNIV,COLL PHARM,SEOUL 132030,SOUTH KOREA
关键词
PHARMACOKINETICS; TISSUE DISTRIBUTION; 5-FLUOROURACIL; 5-FLUOROURACIL ACETIC ACID; 5-FLUOROURACIL-ACETIC ACID-HUMAN SERUM ALBUMIN CONJUGATE;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The pharmacokinetics of 5-fluorouracil (5-FU) was compared after 30 min intravenous infusion of the same dose (20 mg/kg as 5-FU) of 5-FU (treatment I), 5-FU-acetic acid (5-FU-AA, treatment II) and 5-FU-AA-human serum albumin conjugates (5-FU-AA-HSA, treatment III) to rabbits. After post-infusion, plasma levels of 5-FU declined rapidly with a mean half-life of 8.0 min from treatment I, however, they were not detected until 10-50 min and the mean plasma concentration of 1 mu-g/ml was maintained from 3 to 24 h for treatment III. It might be possible to maintain constant plasma concentrations of 5-FU for a long period of time by 30 min infusion of 5-FU-AA-HSA conjugates instead of tedious time-consuming infusion of 5-FU. The mean values of 24 h AUC (623 vs 1290-mu-g min ml-1) were significantly higher from treatment III than that from treatment I. 5-FU was not detected from treatment II nor 5-FU-AA from treatment III in both plasma and urine samples. In treatment II, 5-FU-AA was eliminated rapidly with a mean apparent terminal half-life of 18.7 min based on urinary excretion rate data. 5-FU was not detected in brain after 30 min intravenous infusion of both 5-FU and 5-FU-AA, however, significant amounts of 5-FU were found in brain after administration of 5-FU-AA-HSA conjugates. The in vitro release of 5-FU from 5-FU-AA-HSA conjugates was increased in the presence of protease or liver homogenates, however, 5-FU was not detected for up to 24 h incubation of 5-FU-AA with the various solutions.
引用
下载
收藏
页码:61 / 68
页数:8
相关论文
共 50 条
  • [41] A phase III study of regional 2-weekly 5-fluorouracil infusion with intravenous folinic acid in the treatment of colorectal liver metastases
    Howell, JD
    McArdle, CS
    Kerr, DJ
    Buckles, J
    Ledermann, JA
    Taylor, I
    Gallagher, HJ
    Budden, J
    BRITISH JOURNAL OF CANCER, 1997, 76 (10) : 1390 - 1393
  • [42] A phase II study of regional 2-weekly 5-fluorouracil infusion with intravenous folinic acid in the treatment of colorectal liver metastases
    JD Howell
    CS McArdle
    DJ Kerr
    J Buckles
    JA Ledermann
    I Taylor
    HJ Gallagher
    J Budden
    British Journal of Cancer, 1997, 76 : 1390 - 1393
  • [43] Intravenous weekly high-dose infusion of 5-fluorouracil and folinic acid in previously heavily pretreated patients with metastatic colorectal cancer.
    Piringer, Gudrun
    Huber, Verena
    Burgstaller, Sonja
    Weninger, Martin
    Karrer, Andreas
    Mayrbaeurl, Beate
    Thaler, Josef
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [44] MITOMYCIN-C PLUS A 3-DAY CONTINUOUS INTRAVENOUS-INFUSION OF 5-FLUOROURACIL - AN INACTIVE SALVAGE REGIMEN FOR PLATINUM-RESISTANT OVARIAN-CARCINOMA
    REICHMAN, B
    MARKMAN, M
    HAKES, T
    RUBIN, S
    JONES, W
    CURTIN, J
    BARAKAT, R
    ALMADRONES, L
    LEWIS, JL
    HOSKINS, W
    GYNECOLOGIC ONCOLOGY, 1993, 50 (01) : 30 - 33
  • [45] Durable remission of inoperable liver metastasis from rectal cancer after hepatic arterial infusion of oxaliplatin and 5-fluorouracil in combination with intravenous cetuximab
    Van Bael, K.
    Aerts, M.
    de Ridder, M.
    de Greve, J.
    Delvaux, G.
    Neyns, B.
    CURRENT ONCOLOGY, 2011, 18 (05) : E256 - E259
  • [46] Phase I dose escalation and pharmacokinetics study of intravenous aflibercept plus irinotecan, 5-fluorouracil, and folinic acid (FOLFIRI) in patients with metastatic colorectal cancer
    Yamazaki, K.
    Yeshlno, T.
    Yamaguchi, K.
    Boku, N.
    Machlda, N.
    Onozawa, Y.
    Asayama, M.
    Doi, T.
    Ohtsu, A.
    Aoyama, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [47] Plasma and salivary pharmacokinetics of 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer receiving 5-FU bolus plus continuous infusion with high-dose folinic acid
    Joulia, JM
    Pinguet, F
    Ychou, M
    Duffour, J
    Astre, C
    Bressolle, F
    EUROPEAN JOURNAL OF CANCER, 1999, 35 (02) : 296 - 301
  • [48] Pharmacokinetics of 5-fluorouracil (5-FUra) in patients with metastatic colorectal cancer receiving 5-FUra bolus plus continuous infusion with high dose folinic acid (LV5FU2)
    Joulia, JM
    Pinguet, F
    Ychou, M
    Duffour, J
    Topart, D
    Grosse, PY
    Astre, C
    Bressolle, F
    ANTICANCER RESEARCH, 1997, 17 (4A) : 2727 - 2730
  • [49] Stealth recombinant human serum albumin nanoparticles conjugating 5-fluorouracil augmented drug delivery and cytotoxicity in human colon cancer, HT-29 cells
    Sharma, Ankita
    Kaur, Amanpreet
    Jain, Upendra Kumar
    Chandra, Ramesh
    Madan, Jitender
    COLLOIDS AND SURFACES B-BIOINTERFACES, 2017, 155 : 200 - 208
  • [50] PHASE-I STUDY OF A 120-HOUR CONTINUOUS INTRAVENOUS-INFUSION OF 5-FLUOROURACIL IN PEDIATRIC-PATIENTS WITH RECURRENT SOLID TUMORS - A PEDIATRIC ONCOLOGY GROUP-STUDY
    GREEN, DM
    KRISCHER, JP
    BELL, B
    BRECHER, ML
    CUSHING, B
    WHITEHEAD, VM
    MEDICAL AND PEDIATRIC ONCOLOGY, 1990, 18 (04): : 321 - 324